查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1425055

BFS 注射器市場 - 預測 2024-2029

BFS Syringe Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年BFS注射器市場規模為406,801,000美元。

醫療保健和化妝品行業對 BFS 注射器的需求不斷成長，預計將推動市場擴張。推動市場需求的是現代藥品包裝類型和單位劑量包裝的選擇。製藥公司使用採用吹-灌-封 (BFS) 技術的預填充式注射器。因此，預計 BFS 注射器市場在預測期內將顯著成長。無菌包裝公司擴大在包裝和自動化流程中使用一種稱為吹灌封 (BFS) 的滅菌技術。 BFS技術已獲得FDA（美國食品藥物管理局）認證，用於藥品和保健品的製造，而改進的無菌加工技術正在為BFS注射器市場的擴大創造有利的市場動態。此外，美容注射器（例如精華液和其他護膚品）的使用也預計將刺激市場需求。

介紹

BFS 技術只需很少的人工即可準備，最近在製藥業得到了廣泛的應用。包括美國食品藥物管理局(FDA) 在內的多個監管機構認為該技術是機密藥品無菌填充的首選方法。製藥公司考慮了 BFS 注射器的幾個優點，包括低營運成本、靈活的包裝設計、高無菌性、低勞動力需求和低零件庫存。該技術起源於歐洲，那裡的需求量很大，其次是北美。這種方法常用於製藥業，並且可以使母體製劑的填充受到很少的人為干擾。此外，它也用於填充眼藥水、吸入裝置、靜脈注射液和其他母體製劑。在醫療保健領域，對效率和劑量準確性的重視正在推動注射器技術的進步。自從推出吹灌封 (BFS) 注射器以來，注射器的包裝和用途發生了變化。領先的注射器製造商目前正在轉向 BFS 技術，該技術已被多個監管機構認可為無菌填充藥物的優越技術，從而對市場成長產生積極影響。

促進因素

  • 對無菌填充的需求不斷成長正在推動市場成長：隨著包裝產業自動化的引入，BFS 注射器提供了無菌解決方案並滿足了對無菌條件的需求。使用 BFS 注射器技術的無菌包裝可在每分鐘包裝的清潔物品數量方面提供高精度，最終促進市場成長。
  • 醫藥產業的成長正在推動市場需求：醫藥產業的快速成長正在推動市場的成長。領先的藥品製造商利用最先進的滅菌工藝來最大限度地減少包裝液體藥品時操作員的互動和污染的可能性。
  • 降低 BFS 注射器污染的可能性並創造市場需求：利用自動化 BFS 技術，注射器的製造、填充和密封一步完成。因此，污染的可能性較小，並且被醫療保健專業人員廣泛接受。
  • 這些注射器不需要冷藏儲存，導致價格較低：BFS注射器通常用於呼吸、眼科、口服、預填充式注射器和注射藥物的無菌包裝。這些產品對消費者來說很方便，對供應商來說也很經濟，因為它們不需要冷藏。
  • 新興經濟體對疫苗的需求不斷成長：新興經濟體對疫苗的需求激增是市場開拓的主要因素。隨著印度等國家疫苗接種率的提高，注射器的銷售量預計也會增加。主要注射器製造商也在提高產能，以應對疫苗需求的增加。

主要企業提供的產品

  • 預填充ApiJect 注射器，Apiject：預填充 ApiJect 注射器由 Apiject 提供。
  • BD EffivaxTM 玻璃預充式注射器，Becton，Dickinson and Company：著名的醫療技術提供者BD 開發了下一代玻璃預充式注射器，對可加工性、外觀、耐污性和完整性提出了新的、更嚴格的要求。公牛注射器（PFS）。該 PFS 為疫苗接種 PFS 的性能樹立了新的基準。為了滿足疫苗生產複雜且不斷變化的需求，與頂級製藥公司合作創建了創新的 BD Efivax™ 玻璃預灌封注射器。

從材料來看，聚丙烯領域成長顯著。

製藥業已獲得主要市場佔有率，預計在預測期內也將主導市場。領先的藥品製造商使用最先進的滅菌技術來防止疏忽和污染。吹灌封（BFS）技術提供安全、無菌的包裝，已成為藥品包裝的流行方法。由於醫療保健行業對無菌包裝的需求不斷成長，領先公司正在使用採用這種吹灌封 (BFS) 技術的注射器。注射器在醫療保健中用於降低污染和劑量不準確的風險。此外，消除重複使用的可能性和防止交叉感染也是推動市場成長的主要因素。

歐洲地區預計將佔據 BFS 注射器市場的主要佔有率：

預計歐洲市場在預測期內將大幅擴張。歐洲是藥品製造商的頂級地區。歐洲市場預計將保持其作為 BSF 注射器製造商主要市場的地位。藥品包裝行業的主要參與者位於歐洲市場，並且更喜歡使用吹灌封技術進行注射劑滅菌，這一事實進一步強調了這一點。歐洲公司繼續優先考慮注射包裝，這推動了市場的爆炸性擴張。對管瓶、瓶子、安瓿和預填充式注射器等先進無菌包裝的需求正在推動製藥業擴大使用吹灌-封 (BFS) 技術。

主要進展

  • 知名醫療設備供應商 BD 的下一代玻璃預充式注射器 (PFS) 將於 2022 年 9 月發布，其在加工性能、外觀、抗污染性和完整性方面均具有新增強的規格。該 PFS 為免疫 PFS 領域設定了新的性能標準。革命性的 BD Efivax™ 玻璃預充式注射器是與領先的製藥公司合作開發的，以滿足疫苗生產複雜且不斷變化的要求。
  • Becton Dickinson & Company 宣布有意於 2021 年 11 月在西班牙投資新製造工廠。此舉可能讓該公司提高預充式注射器的生產能力。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 調查資料
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章 BFS 注射器市場：按容量

  • 介紹
  • 0.5～1ml
  • 1～3ml
  • 3ml以上

第6章 BFS 注射器市場：依材料分類

  • 介紹
  • 聚丙烯（PP）
  • 聚氯乙烯（PVC）
  • 其他

第 7 章 BFS 注射器市場：依最終使用者分類

  • 介紹
  • 製藥/醫療保健
  • 個人護理和化妝品
  • 其他

第8章 BFS 注射器市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第10章 公司簡介

  • BREVETTI ANGELA Srl
  • Recipharm AB
  • The Ritedose Corporation
  • Amanta Healthcare
  • ApiJect Systems, Corp.
  • SIFI SpA
  • LyondellBasell Industries Holdings BV
簡介目錄
Product Code: KSI061616092

The BFS syringe market was valued at US$406.801 million in 2022.

The healthcare and cosmetics industries' rising need for BFS syringes is anticipated to fuel market expansion. The market demand is being driven by the choice of modern pharmaceutical packaging types and unit dosage packaging. Pharmaceutical businesses utilize prefilled syringes with blow-fill seal (BFS) technology. Throughout the projection period, a considerable increase in the market for BFS syringes is anticipated as a result of this. Aseptic packaging companies are increasingly using the sterilizing technique known as blow-fill-seal (BFS) for packaging and automated processes. The BFS technology has received FDA (Food and Drug Administration) certification for use in the production of pharmaceutical and healthcare products employing an improved aseptic processing technique which has created favorable market dynamics for expansion of the BFS syringe market. The demand in the market is also anticipated to be fueled by the usage of these syringes for cosmetics items in serum applications and other skincare products.

Introduction:

To offer parental preparation with very little human involvement, BFS technology has recently received great application in the pharmaceutical business. Several regulating organizations, including the US Food and Drug Administration (FDA), view this technique as a preferable approach for aseptic filling of parental preparation. Pharmaceutical packaging companies take into account several benefits of BFS syringes, including their cheap operating costs, flexible package designs, high levels of sterility, low labour demand, and small component inventories. The technology was created in Europe, where it is in high demand, followed by North America. The method is commonly used in the pharmaceutical industry to fill the parental preparation with fairly little human interference. Additionally, it is used to fill eye drops, inhalation devices, intravenous fluids, and other parent preparations. The healthcare sector's emphasis on efficiency and dose precision has sparked advancements in syringe technology. The packaging and use of syringes are changing with the introduction of blow-fill-seal (BFS) syringes. Leading syringe producers are now progressively migrating to BFS technology, which is regarded as a superior technique for aseptically filling parental preparation by several regulatory organizations which has consequently positively influenced market growth.

Drivers:

  • Rise in demand for aseptic packing is fueling market growth: With the introduction of automation in the packing business, BFS syringes provide a sterile solution and meet the demand for aseptic conditions. In terms of the number of clean items packed per minute, aseptic packaging using BFS syringe technology offers high precision which eventually fuels market growth.
  • Growth of the pharma industry is propelling market demand: The exponential growth in the pharma sector is a prime reason for boosting market growth. Leading pharmaceutical producers utilize cutting-edge sterilizing processes to minimize operator interaction and the possibility of contamination while packing liquid pharmaceuticals. It is a desirable technique for medicine packaging because it provides flexible diversity in packaging design, cost-effectiveness, sterility, and low component inventory.
  • BFS syringes reduce the chance of contamination hence creating market demand: Using automated BFS technology, syringes are manufactured, filled, and sealed all in one step. As a result, it reduces the chance of contamination and is therefore widely accepted among healthcare professionals.
  • These syringes do not require refrigeration for their storage which consequently reduces prices: For the aseptic packing of respiratory, ophthalmic, oral, and pre-filled syringes, and injectable pharmaceuticals, a BFS syringe is often used. These products are handy for consumers and cost-effective for vendors because they don't require refrigeration and therefore are economical.
  • Growing demand for vaccines from emerging economies: The surge in demand for vaccines from emerging economies is a major factor for market development. Syringe sales are expected to increase as immunization rates rise in nations like India. The main maker of syringes has also increased their production capacity as a result of the increasing demand for vaccinations.

Products offered by key companies:

  • Prefilled ApiJect Injector, Apiject: Prefilled ApiJect Injector is offered by Apiject. It is a delivery device created to combine the advantages of prefilled syringes with the manufacturing effectiveness of multi-dose presentations.
  • BD EffivaxTM Glass Prefillable Syringe, Becton, Dickinson and Company: BD, a prominent provider of medical technology unveiled a next-generation glass pre-fillable syringe (PFS) with new and stricter requirements for processability, cosmetics, contamination, and integrity. This PFS establishes a new benchmark in performance for vaccination PFS. To fulfil the complicated and changing demands of vaccine manufacture, the innovative BD EffivaxTM Glass Prefillable Syringe was created in partnership with top pharmaceutical firms.

The prominent growth in the Polypropylene sector under the material type segment

The pharmaceutical sector captured the major market share and is predicted to dominate the market over the forecast period. Leading pharmaceutical manufacturers prevent oversights and contamination by using cutting-edge sterilization technologies. Blow-fill-seal (BFS) technology provides safe and sterile packaging, making it a popular method for medicine packaging. Leading companies use these syringes utilizing the blow-fill-seal (BFS) technology in response to the growing need for aseptic packaging in the healthcare industry. Syringes are used in healthcare to lessen the danger of contamination and dose inaccuracy. Additionally, it eliminates the chance of reuse, preventing cross-infection which as a result is a major factor driving the market growth.

European region is expected to hold a significant share of the BFS syringe market:

The European market is poised to expand significantly over the projection period. Europe is a top-tier region concerning pharmaceutical producers. The market players located in the European market are extensively involved in the export of pharma products The European market is forecasted to sustain its position as a top market for BSF syringe manufacturers. Pharmaceutical packaging industry giants have established bases in the European market, and they have a preference for blow-fill-seal technology to sterilize injectables, which serves to emphasize this even more. European-based businesses have continued to prioritize injectable packaging, which is fueling the market's explosive expansion. The demand for sophisticated aseptic packaging, such as vials, bottles, ampoules, and pre-filled syringes, is driving an increase in the use of blow-fill-seal (BFS) technology in the pharmaceutical industry.

Key developments:

  • A next-generation glass pre-fillable syringe (PFS) from BD, a well-known supplier of medical equipment, was introduced with new and tighter specifications for processability, cosmetics, contamination, and integrity in September 2022. This PFS sets a new standard for performance in the field of immunization PFS. In collaboration with leading pharmaceutical companies, the ground-breaking BD EffivaxTM Glass Prefillable Syringe was developed to meet the complex and ever-changing requirements of vaccine manufacturing.
  • Becton, Dickinson, and Company declared their intention to invest in a new manufacturing facility in Spain in November 2021. The company may be able to increase its capacity for pre-fillable syringe production as a result of this action.

SEGMENTS:

BY CAPACITY

  • 0.5-1 ml
  • 1-3 ml
  • Above 3 ml

BY MATERIAL

  • Polypropylene (PP)
  • Polyvinyl Chloride (PVC)
  • Others

BY END-USER

  • Pharmaceutical and Healthcare
  • Personal Care and Cosmetics
  • Others

BY GEOGRAPHY

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. BFS SYRINGE MARKET, BY CAPACITY

  • 5.1. Introduction
  • 5.2. 0.5-1 ml
  • 5.3. 1-3 ml
  • 5.4. Above 3 ml

6. BFS SYRINGE MARKET, BY MATERIAL

  • 6.1. Introduction
  • 6.2. Polypropylene (PP)
  • 6.3. Polyvinyl Chloride (PVC)
  • 6.4. Others

7. BFS SYRINGE MARKET, BY END-USERS

  • 7.1. Introduction
  • 7.2. Pharmaceutical and Healthcare
  • 7.3. Personal Care and Cosmetics
  • 7.4. Others

8. BFS SYRINGE MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. BREVETTI ANGELA S.r.l.
  • 10.2. Recipharm AB
  • 10.3. The Ritedose Corporation
  • 10.4. Amanta Healthcare
  • 10.5. ApiJect Systems, Corp.
  • 10.6. SIFI S.p.A
  • 10.7. LyondellBasell Industries Holdings B.V.

Not an exhaustive list